Free tool
FAERS Monitor: Argatroban In Sodium Chloride
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022485 or its brand name (Argatroban In Sodium Chloride, Argatroban). Reports on generic versions are filed under their own applications.
Reports
1,499
Serious
1,309
87% of reports
Hospitalization
637
Death reported
321
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- heparin-induced thrombocytopenia191
- drug ineffective157
- international normalised ratio increased110
- off label use99
- activated partial thromboplastin time prolonged83
- haemorrhage81
- pulmonary embolism70
- thrombocytopenia70
- deep vein thrombosis69
- coagulation time prolonged64
- thrombosis56
- gastrointestinal haemorrhage54
- cerebral infarction50
- platelet count decreased39
- cerebral haemorrhage38
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 20 |
| 2005 | 22 |
| 2006 | 42 |
| 2007 | 64 |
| 2008 | 48 |
| 2009 | 47 |
| 2010 | 195 |
| 2011 | 99 |
| 2012 | 74 |
| 2013 | 39 |
| 2014 | 43 |
| 2015 | 47 |
| 2016 | 32 |
| 2017 | 68 |
| 2018 | 53 |
| 2019 | 87 |
| 2020 | 86 |
| 2021 | 94 |
| 2022 | 92 |
| 2023 | 69 |
| 2024 | 61 |
| 2025 | 83 |
| 2026 | 34 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,660 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| coagulation time prolongedSignal | 64 | 605.3 | 473.7 | 36,441 |
| heparin-induced thrombocytopeniaSignal | 191 | 565.8 | 494.1 | 102,999 |
| activated partial thromboplastin time prolongedSignal | 83 | 233.8 | 189.4 | 18,704 |
| international normalised ratio increasedSignal | 110 | 54.3 | 45.4 | 5,692 |
| cerebral infarctionSignal | 50 | 28.8 | 21.9 | 1,312 |
| deep vein thrombosisSignal | 69 | 14.9 | 11.8 | 884 |
| cerebral haemorrhageSignal | 38 | 14.9 | 10.9 | 480 |
| haemorrhageSignal | 81 | 10.9 | 8.8 | 720 |
| pulmonary embolismSignal | 70 | 10.3 | 8.2 | 584 |
| thrombosisSignal | 56 | 9.8 | 7.6 | 434 |
| gastrointestinal haemorrhageSignal | 54 | 9.1 | 7.0 | 381 |
| thrombocytopeniaSignal | 70 | 8.8 | 7.0 | 478 |
| platelet count decreasedSignal | 39 | 5.1 | 3.8 | 126 |
| drug ineffective | 157 | 1.7 | 1.4 | 44 |
| off label use | 99 | 1.6 | 1.3 | 22 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.